NCT03911557: Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: TMB-H
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with untreated unstable brain metastases – see trial for details; Patients with a history of leptomeningeal carcinomatosis; Patients previously treated with anti-PD-1/PD-L1 including durvalumab or anti-CTLA-4 immunotherapy including tremelimumab

Comments are closed.

Up ↑